Rockwell Medical Technologies (NASDAQ: RMTI) reported Q3 EPS of ($0.10), versus $0.00 reported last year. Revenue for the quarter came in at $16.67 million versus the consensus estimate of $15 million.

Mr. Paul said, "Since joining Rockwell Medical as President and CEO in early September, one of my priorities has been undertaking a top-to-bottom review of the Company. It has become increasingly clear to me that Dialysate Triferic and IV Triferic present a fundamental opportunity to positively impact patients in the dialysis community and global anemia market, while simultaneously creating value for all our stakeholders. The management team and I have been preparing for the U.S. commercialization of Dialysate Triferic, and are working toward a U.S. launch in the first half of 2019. Given the sizable market opportunity, we are also moving ahead with regulatory filings and the development of activities related to IV Triferic, which has significant potential to help patients both in the U.S. and abroad. If approved by the FDA, we are planning for a U.S. launch in the first half of 2020. In addition to Triferic-related activities, we are carefully studying the commercial opportunity for Calcitriol and are working to improve the overall economics in our Concentrates products given the profitability and strategic potential for this business line."

Mr. Paul added, "As part of my review to better understand our products and our operations, I've spent time over the last 70 days getting to know the fantastic Rockwell Medical team. Together with our newly appointed senior leaders, I am energized by the opportunities ahead as we work to realize the full potential of the Company\'s valuable assets, improve patient outcomes and create shareholder value."

For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.